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Introduction {#sec1}
============

Lung cancer is the leading cause of cancer deaths worldwide. At the time of diagnosis, metastatic dissemination is seen in many patients with either non-small-cell lung cancer (NSCLC) or small cell lung cancer (SCLC) ([@bib47]). The overall 5-year survival rate for lung cancer is still only 10%--15% ([@bib47]). The brain is the most common site for lung cancer metastasis; 25%--30% of patients with NSCLC and 80% of patients with SCLC will develop brain metastasis during the course of their disease. Because the blood-brain barrier (BBB) is impermeable to most chemotherapeutic drugs used for lung cancer, the only available therapies for brain metastases include whole-brain irradiation or surgical resection in eligible patients. Although some small-molecule tyrosine kinase inhibitors have shown efficacy in a subset of patients, the results have not been consistent owing to the relatively low cerebrospinal fluid (CSF)-to-plasma ratios ([@bib22]). Therefore, discovering novel small molecule agents that can inhibit both primary and metastatic lung cancer, including brain metastases, is a critical unmet need.

Although many tumor cells rely on aerobic glycolysis as the major source of adenosine triphosphate (ATP) to fuel cell proliferation (the Warburg effect), increasing evidence indicates that mitochondria are indeed functional in most tumor cells ([@bib7], [@bib10], [@bib9], [@bib8], [@bib67], [@bib4]). Recent profiling of cellular bioenergetics has provided new insights on the intermediacy of mitochondrial metabolism in tumor cells ([@bib7], [@bib10], [@bib9], [@bib8], [@bib67], [@bib4]). Cancer cells without mitochondrial DNA (mtDNA), called rho0 or ρ0 cells, show delayed tumor formation ([@bib60]). However, mtDNA can be acquired by transfer of whole mitochondria from the host animal, which normalizes mitochondrial respiration and restores tumorigenic potential ([@bib16]). Furthermore, several anti-cancer agents were recently identified that specifically target mitochondrial function, such as resveratrol ([@bib71]) or metformin ([@bib70]). Thus, targeting mitochondrial bioenergetics is emerging as a promising and viable therapeutic approach to inhibit the proliferation of both poorly glycolytic and highly glycolytic cancer cells ([@bib7], [@bib10], [@bib9], [@bib8], [@bib67], [@bib68]). Honokiol (HNK), a key bioactive compound present in magnolia bark extracts, exhibits anti-cancer and anti-metastatic properties in a variety of *in vitro* and *in vivo* models ([@bib43], [@bib1]). We previously demonstrated that high-dose HNK (37.5 μmol/kg) inhibits the development of squamous cell carcinoma (SCC) in a carcinogen-induced mouse model ([@bib45]), in which HNK was shown to suppress mitochondrial respiration, decrease ATP levels, and increase the generation of reactive oxygen species (ROS) ([@bib45]). Thus even though HNK is not specifically sequestered inside mitochondria, these findings revealed that HNK can directly target mitochondrial bioenergetics, leading to persistent inhibition of mitochondrial respiration in lung cancer cells ([@bib45]). We therefore hypothesized that conjugating HNK to a compound that drives HNK into mitochondria should dramatically increase its antitumor efficacy and potency. There is ample evidence in the literature that supports the therapeutic efficacy of mitochondria-targeted triphenylphosphonium (TPP^+^)-linked agents in cellular and animal models and possibly in humans ([@bib39], [@bib21], [@bib61], [@bib56], [@bib38], [@bib54], [@bib55]). We therefore developed mitochondria-targeted honokiol (Mito-HNK) by attaching the bulky TPP^+^ group to HNK via a long alkyl chain, well separated from HNK\'s aromatic structure. Published reports also indicate that increasing the lipophilicity of TPP^+^-conjugated compounds enhances their cellular and mitochondrial uptake ([@bib53], [@bib2], [@bib50], [@bib18]). Lipophilic cations, including TPP^+^-based agents, selectively accumulate in cancer cells *in vitro* and *in vivo* owing to an elevated mitochondrial membrane potential ([@bib58], [@bib28], [@bib49], [@bib37], [@bib10]). Another rationale for using Mito-HNK in this lung cancer brain metastasis study is the observation that the TPP^+^-based compound, \[^11^C\]-triphenylmethylphosphonium (TPMP), selectively accumulates in brain tumors ([@bib34]).

Here we describe the synthesis and detailed *in vitro* and *in vivo* characterization of Mito-HNK. In human NSCLC lines derived from brain metastases and in an SCLC line with high metastatic potential, Mito-HNK proved to be more than 100-fold more potent than HNK in inhibiting cell proliferation, suppressing mitochondrial bioenergetics by inhibiting complex I, and stimulating ROS generation. To further support its mitochondrial effects, Mito-HNK oxidized mitochondrial peroxiredoxin-3 (Prx3) and suppressed the phosphorylated form of *mito*STAT3, which functions as a positive regulator of the mitochondrial electron transport chain through non-canonical STAT3 signaling in mitochondria ([@bib73]). Mito-HNK also effectively suppressed the invasion of NSCLC and SCLC cells. *In vivo*, low-dose Mito-HNK (3.75 μmol/kg) markedly suppressed the growth of NSCLC and SCLC lines in a lung orthotopic model and inhibited the growth and progression of lung cancer brain metastases. Within the brain metastases in mice, Mito-HNK induced mediators of cell death in the tumors, and it decreased pathways that support invasion and proliferation. In contrast, in the non-malignant stroma, Mito-HNK suppressed pathways that support metastatic lesions, including those involved in inflammation and angiogenesis. Even at doses 20-fold higher than those that were effective, Mito-HNK exhibited no toxicity in mice over 8 weeks of administration. Mito-HNK is therefore a safe agent that targets the metabolic vulnerabilities of primary and metastatic lung cancers. Its pronounced anti-invasive and anti-metastatic effects against brain metastases are particularly intriguing given the paucity of treatment options for such patients.

Results {#sec2}
=======

Synthesis and Toxicity of Mitochondria-Targeted HNK {#sec2.1}
---------------------------------------------------

Two Mito-HNKs were synthesized by reacting HNK with the bromodecyl-TPP^+^ cation, generating HNK with one TPP^+^ (Mito-HNK) or two TPP^+^ (bis-Mito-HNK) moieties ([Figure 1](#fig1){ref-type="fig"}A). The products were isolated by gel chromatography and purified by preparative high-performance liquid chromatography (HPLC), and their structures were characterized by nuclear magnetic resonance (NMR) and mass spectrometry (MS) ([Figures S1--S3](#mmc1){ref-type="supplementary-material"}; [Figure S3](#mmc1){ref-type="supplementary-material"} related to [Figure 1](#fig1){ref-type="fig"}). To assess the potential toxicity of Mito-HNK, an 8-week subchronic toxicity study was conducted in A/J mice. As neurons and muscle cells may have a relatively high plasma membrane potential that might enhance the uptake of Mito-HNK, we used a modified Irwin screen that was developed as a comprehensive observational battery to broadly screen for central nervous system (CNS) and neuromuscular effects of agents ([@bib24], [@bib12]). Modifications of this test are extensively used in the pharmaceutical industry and in academic research to identify many possible changes in neurological function ([@bib32], [@bib12]). The screen we used employed 35 distinct measurements to assess sensorimotor, neurological, and autonomic nervous system function ([@bib42]). We included mice treated with vehicle control and with various doses of Mito-HNK (7.5, 37.5, and 75 μmol/kg, which represent 2×, 10×, and 20× of the effective dose, respectively) ([Figure 1](#fig1){ref-type="fig"}B), given via oral gavage 5 days per week for 8 weeks. After 8 weeks of treatment, we did not observe any significant differences between control mice and those treated with any dose of Mito-HNK, including the highest dose (75 μmol/kg) ([Figures 1](#fig1){ref-type="fig"}B and 1C; [Table S1](#mmc1){ref-type="supplementary-material"}, related to [Figure 1](#fig1){ref-type="fig"}), for any of the 35 metrics tested. Furthermore, no histopathological changes were seen in either neural (frontal cortex and cerebellum) or muscle tissue (skeletal muscles including the soleus, plantaris, gastrocnemius, tibialis anterior, and quadriceps) (*data not shown*). Thus Mito-HNK did not show any indications of toxicity at a dose that is 20-fold higher than the effective dose.Figure 1Design, Synthesis, and Subchronic Toxicity Screen of Mito-HNK(A) Synthesis of Mito-HNK. Both mono-substituted (Mito-HNK) and double-substituted (Bis-Mito-HNK) mitochondria-targeted derivatives of honokiol were synthesized. The products were purified by HPLC and characterized by NMR and mass spectrometry. TPP^+^-linked compounds accumulate selectively in cancer cell mitochondria, according to the Nernst equation.(B and C) Examples of subchronic toxicity screen of Mito-HNK. (B) Measured body weight (squares, left axis) and rectal temperature (circles, right axis). (C) Latency to fall in the inverted screen test measured after 8 weeks of treatment. The 2×, 10×, and 20× doses relate to the effective dose (1× = 3.5 μmol/kg) and correspond to 7.5, 37.5, and 75 μmol/kg, respectively. Error bars represent standard deviation (SD), n = 5 mice per group. Error bars indicate SE.

Mito-HNK Inhibits Lung Cancer Cell Proliferation and Tumor Growth {#sec2.2}
-----------------------------------------------------------------

Before conducting lung cancer brain metastases studies, *in vitro* studies compared the effects of Mito-HNK and bis-Mito-HNK on the proliferation of lung cancer brain metastatic H2030-BrM3 and PC9-BrM3 cells. Mito-HNK inhibits H2030-BrM3 lung cancer cell proliferation at significantly lower levels (IC~50~ = 0.26 μM) than HNK (IC~50~ = 27 μM) ([Figure 2](#fig2){ref-type="fig"}A). The double-substituted HNK analog (bis-Mito-HNK) is also significantly more potent than HNK (IC~50~ = 0.8 μM, [Figure 2](#fig2){ref-type="fig"}A), but not as potent as Mito-HNK. Because Bis-Mito-HNK has both hydroxyl groups substituted, it is unlikely to be easily metabolized to a quinone methide, suggesting other mechanism(s) of action. In subsequent experiments, we used the more potent mono-substituted analog, Mito-HNK. We verified that the more than 100-fold enhancement in anti-proliferative properties of Mito-HNK versus HNK is due to its targeting to mitochondria, because of the attached TPP^+^ moiety. Liquid chromatography-mass spectrometry (LC-MS/MS) analysis of the fractions from H2030-BrM3 cells treated for 1 hr with 1 μM Mito-HNK showed mitochondrial accumulation of Mito-HNK (0.6 nmoles versus 4.3 nmoles in cytosolic versus mitochondrial fractions per 10^6^ cells, respectively). Also, treatment of cells (0.1 μM, 24 hr) led to significantly higher mitochondrial accumulation of Mito-HNK than HNK ([Figure 2](#fig2){ref-type="fig"}B). Combinations of HNK or decyl-HNK with Me-TPP^+^ (see [Figure 2](#fig2){ref-type="fig"}C for chemical structures) failed to reproduce the anti-proliferative effects of Mito-HNK ([Figures 2](#fig2){ref-type="fig"}D and 2E). Thus, attaching TPP^+^ to HNK markedly increases mitochondrial accumulation and anti-proliferative activity in lung cancer cells.Figure 2Mito-HNK Inhibits the Proliferation and Tumor Growth of Lung Cancer Cells(A) Mito-HNK and *bis*-Mito-HNK inhibit the proliferation of H2030 cells at significantly lower concentrations than HNK. The IC~50~ values were determined at the point when untreated cells reached ∼95% confluence (∼4 days of incubation).(B) Treatment of H2030-BrM3 cells (0.1 μM, 24 hr) leads to significantly higher mitochondrial accumulation of Mito-HNK than HNK (\*\*\*P \< 0.001 vs. HNK).(C) The chemical structures of Mito-HNK and the control compounds (Dec-HNK and Me-TPP^+^) used for data in panels D and E.(D and E) The combinations of HNK or decyl-HNK with Me-TPP^+^ fail to reproduce the anti-proliferative effects of Mito-HNK. The traces recorded during real-time monitoring of cell confluence are shown in (D), and the cell confluence after 5 days of incubation with the compounds (1 μM) is shown in (E).(F) Representative bioluminescence live imaging of NSCLC orthotopic tumor growth in control or Mito-HNK-treated mice (3.75 μmol/kg each).(G) Quantitative data for bioluminescence imaging of the orthotropic growth of NSCLC (H2030-Br3M) cells (n = 6 per group, observation duration = 21 days).(H) Quantitative data for the bioluminescence imaging of the orthotropic growth of SCLC (DMS-273) cells (n = 6 per group, observation duration = 15 days).(I) Left panel, representative immunohistochemistry staining of H2030-BrM3 orthotopic lung tumors for Ki-67 in control and Mito-HNK-treated groups; right panel, quantitative estimation of cell proliferation showing percentage of Ki-67+ cells (\*\*p \< 0.01 versus control).(J) Representative H&E staining images of H2030-BrM3 orthotopic lung tumors taken from control and Mito-HNK groups. Error bars indicate SE.

Next, we evaluated the efficacy of Mito-HNK in lung tumor growth using an orthotopic model of lung cancer in NOD/SCID mice. At 8 weeks of age, H2030-BrM3 (NSCLC) or DMS-273 (SCLC) cells were injected into the left lung of mice. After 1 week, mice were treated by oral gavage 5 days per week with Mito-HNK (3.75 μmol/kg) or vehicle (corn oil). During the treatment, the progression of lung tumors was monitored by bioluminescence imaging. As shown in [Figures 2](#fig2){ref-type="fig"}F--2H, Mito-HNK (3.75 μmol/kg) reduced tumor size by ∼70% (H2030-BrM3 cells) or ∼40% (DMS-273 cells) when compared with control mice, whereas the same dose of HNK failed to decrease lung tumor growth (data not shown). However, in our previous study, a 10-fold higher dose of HNK (37.5 μmol/kg) was effective in decreasing lung tumor growth ([@bib44]). Immunohistochemistry of serial sections showed a significant reduction in the proliferation marker Ki-67 in Mito-HNK-treated tumors ([Figure 2](#fig2){ref-type="fig"}I). Hematoxylin and eosin (H&E) staining did not reveal other morphological changes upon Mito-HNK treatment ([Figure 2](#fig2){ref-type="fig"}J).

Mito-HNK Inhibits Invasion and Brain Metastasis of Lung Cancer Cells {#sec2.3}
--------------------------------------------------------------------

The Boyden chamber invasion assay, which was used to assess anti-metastatic potential, showed that Mito-HNK (48 hr) suppressed the *in vitro* invasion of both brain metastatic NSCLC lines in a dose-dependent manner ([Figures 3](#fig3){ref-type="fig"}A and 3C ). Similarly, Mito-HNK inhibited the invasion of the SCLC line in a dose dependent manner (DMS-273) ([Figures 3](#fig3){ref-type="fig"}B and 3D) and was over 100-fold more potent than HNK ([@bib44]). To rule out the possibility of pro-apoptotic or cytotoxic effects of Mito-HNK, the invasion assay was also conducted in lung cancer cells pretreated with Mito-HNK; as shown in [Figure S4](#mmc1){ref-type="supplementary-material"}A; wells pretreated with Mito-HNK had significantly less cell invasion compared to control wells, while at these doses Mito-HNK did not cause significant cell death or pro-apoptotic activities, but rather blocked cell cycling machinery ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C, related to [Figure 3](#fig3){ref-type="fig"}), indicating that Mito-HNK directly inhibits cancer cell invasion.Figure 3Mito-HNK Inhibits Invasion and Brain Metastasis of Lung Cancer Cells(A and C) The anti-invasive effects of Mito-HNK on NSCLC lines H2030-BrM3 and PC9-BrM3 were assessed via the Boyden chamber invasion assay after 48-hr treatment. Representative images are shown in (A) and the quantitative data are shown in (C, \*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001 vs*.*control).(B and D) Representative images (B) and quantitative data (D) of the invasion assay for SCLC DMS-273 cells indicate that Mito-HNK is at least 100-fold more potent than HNK (\*P \< 0.05, \*\*P \< 0.01 vs*.*control).(E) High-resolution echocardiography to visualize the needle position within the left cardiac ventricle, for injecting lung cancer cells in the *in vivo* experiments to establish brain metastases.(F) Representative bioluminescence, GFP expression, and H&E staining images of brains taken from control, HNK, and Mito-HNK (3.75 μmol/kg each) mice.(G and H) Quantitative data for the bioluminescence imaging of brain metastases over time. Mito-HNK treatment was started 1 day after injection of H2030-BrM3 cells (G, n = 6 for control, and n = 5 for Mito-HNK, observation duration = 27 days) or DMS-273 cells (H, n = 7 each, observation duration = 14 days). (G, *inset)* shows the LC-MS trace from a brain extract indicating the presence of Mito-HNK (65 pmol/g of whole brain tissue). Error bars indicate SE.

To investigate the effect of Mito-HNK on *in vivo* metastasis, we used a previously characterized experimental lung cancer brain metastasis model to generate brain metastases in mice ([@bib41], [@bib44]). We generated green fluorescent protein (GFP)-luciferase-expressing variants of each lung cancer cell line (both NSCLC and SCLC) and confirmed that they efficiently formed brain metastases. We used an ultrasound-guided procedure to secure the precise injection of brain-seeking lung cancer cells into the left cardiac ventricle of NOD/SCID mice as described previously ([@bib44]). These injected lung cancer cells rapidly colonized the cerebrum and cerebellum, forming many nodules in animals treated with vehicle control ([Figure 3](#fig3){ref-type="fig"}F). Mito-HNK (3.75 μmol/kg) was administered by oral gavage starting 1 day after engrafting lung cancer cells in the arterial circulation; brain metastases were monitored by bioluminescence upon injection of luciferin. Mito-HNK inhibited the growth of lung cancer brain metastases of both NSCLC (H2030-BrM3) ([Figure 3](#fig3){ref-type="fig"}G) and SCLC (DMS-273) ([Figure 3](#fig3){ref-type="fig"}H) cells. Metastases were confirmed by *ex vivo* GFP imaging, H&E, and GFP immunostaining ([Figure 3](#fig3){ref-type="fig"}F). LC-MS analyses of brain extracts ([Figure 3](#fig3){ref-type="fig"}G) confirm that Mito-HNK crosses the BBB. These results show that Mito-HNK is a potent inhibitor of lung cancer brain metastases for both the NSCLC and SCLC models used.

Mito-HNK Inhibits Complex I, Promotes ROS Generation, and Oxidizes Mitochondrial Peroxiredoxin-3 {#sec2.4}
------------------------------------------------------------------------------------------------

We previously found that HNK blocks squamous cell lung cancer progression by inhibiting cellular respiration (or oxygen consumption rate \[OCR\]) and mitochondrial function ([@bib45]). Here, we determined the effect of Mito-HNK on mitochondrial respiration. To test the activity on mitochondrial complexes, the cells were pretreated for 24 hr with Mito-HNK or HNK, followed by measuring the activities of mitochondrial respiratory complexes using the Seahorse XF96 extracellular flux analyzer. This approach provides high throughput, does not require cell fractionation, and can monitor the effect on complexes I and II in a single run. While establishing the model systems, we observed that rotenone (complex I inhibitor) blocks OCR, which can be restored by adding succinate (complex II substrate), whereas in the presence of malonate (complex II inhibitor), the addition of succinate does not stimulate OCR ([Figure S5](#mmc1){ref-type="supplementary-material"}, related to [Figure 4](#fig4){ref-type="fig"}). Antimycin A (complex III inhibitor) decreases both pyruvate- and succinate-driven OCR. These studies established the validity of these mitochondrial complex assays, in agreement with the published protocol ([@bib51]). Next, we compared the ability of HNK and Mito-HNK to inhibit mitochondrial complex I in H2030-BrM3 and DMS-273 cell lines. Mito-HNK was greater than 100-fold more potent than HNK in inhibiting complex I both in H2030-BrM3 ([Figure 4](#fig4){ref-type="fig"}A) and DMS-273 ([Figure 4](#fig4){ref-type="fig"}B) cells.Figure 4Effects of Mito-HNK on Mitochondrial Complex I Activity, ROS, and the Redox State of PeroxiredoxinsTo measure complex I activity, cells were pretreated for 24 hr with Mito-HNK and HNK, the cell membrane was permeabilized, and OCR was measured upon the addition of mitochondrial substrates/inhibitors.(A and B) Both HNK (IC~50~ = 30 μM for both cell lines) and Mito-HNK (IC~50~ = 0.1 μM for both cell lines) inhibit complex I in H2030-BrM3 NSCLC cells (A) and DMS-273 SCLC cells (B).(C and D) The effect of Mito-HNK (1 μM, 24 hr treatment) on cellular ROS production, as measured by HPLC-based profiling of the oxidation products of the HE probe in H2030-BrM3 (C) and DMS-273 (D) cells. The compound 2-hydroxyethidium (2-OH-E^+^) is a specific product for superoxide and diethidium (E^+^-E^+^) is a marker product for one-electron oxidants. HPLC traces are shown in the left panels and the quantitative results in the right panels (\*\*p \< 0.01, \*\*\*p \< 0.001).(E and F) The 24-hr treatment of H2030-BrM3 cells with 0.2 μM Mito-HNK (E) or DMS-273 cells with 0.3 μM Mito-HNK (F) leads to significant oxidation of mitochondrial Prx3, whereas the oxidation state of cytosolic Prx1 is not significantly affected (\*\*P \< 0.01, \*\*\*P \< 0.001 *vs.*control). Error bars indicate SD.

We hypothesized that inhibition of mitochondrial complex I by Mito-HNK would lead to increased ROS levels in lung cancer cells. Indeed, 2-OH-E^+^, the O~2~^⋅--^-specific product of hydroethidine (HE) oxidation, was significantly increased in H2030-BrM3 and DMS-723 cells treated with Mito-HNK ([Figures 4](#fig4){ref-type="fig"}C, 4D, and [S6](#mmc1){ref-type="supplementary-material"}; Figure S6 related to [Figure 4](#fig4){ref-type="fig"}). A strong induction of one-electron oxidation of HE with the formation of diethidium (E^+^-E^+^) was also observed, indicating that Mito-HNK also induces the generation of another stronger oxidant in both H2030-BrM3 and DMS-273 cells ([Figures 4](#fig4){ref-type="fig"}C and 4D). Mito-HNK induced oxidant production at a 100-fold lower concentration than is required for HNK ([Figure S6](#mmc1){ref-type="supplementary-material"}, related to [Figure 4](#fig4){ref-type="fig"}). To assess if mitochondrial oxidative stress occurs as a result of Mito-HNK-induced ROS, we tested the oxidation status of cytosolic (Prx1) and mitochondrial (Prx3) peroxiredoxins in lung cancer cells treated for 24 hr with Mito-HNK, using doses that inhibit complex I by 60%--80% (as shown in [Figures 4](#fig4){ref-type="fig"}A and 4B). In all three lung cancer lines, these treatments caused significant oxidation of mitochondrial Prx3 but relatively little effect on the redox status of cytosolic Prx1 (examples shown in [Figures 4](#fig4){ref-type="fig"}E and 4F, with the data for PC9-BrM3 cells shown in [Figure S7](#mmc1){ref-type="supplementary-material"}; Figure S7 related to [Figure 4](#fig4){ref-type="fig"}). This implies that Mito-HNK-induced ROS formation occurs primarily in the mitochondria, consistent with its site of accumulation.

Mitochondrial DNA Depletion Abrogates Mito-HNK\'s Effect on Cancer Cell Proliferation {#sec2.5}
-------------------------------------------------------------------------------------

Mitochondria are vital organelles and the powerhouse of eukaryotic cells. mtDNA, encodes for 13 proteins of the ∼1,500 total that comprise the mitochondrial proteome. All 13 mtDNA-encoded proteins are subunits of mitochondrial respiratory complexes and are therefore critical for the bioenergetic machinery. Mutations and copy number changes in mtDNA are often linked with cancer development. A recent study showed that tumor cells without mtDNA (ρ0 cells) have delayed tumor growth ([@bib60], [@bib16]), and the transfer of intact mitochondria with their mtDNA from host cells to the tumor cells can restore the tumor cells\' respiration and tumor formation efficacy. To delineate the involvement of mitochondria in Mito-HNK\'s anti-cancer effects, we tested Mito-HNK in these same ρ0 cells. ρ0 Cells showed no mitochondrial complex I and complex II activities compared with parental cells ([Figures 5](#fig5){ref-type="fig"}A and 5B, left panels), which is consistent with the absence of mitochondria in ρ0 cells. PicoGreen DNA staining revealed a complete loss of mtDNA in both ρ0 cell lines ([Figures 5](#fig5){ref-type="fig"}A and 5B, right panel, bottom row, arrows). In contrast, the parental lines that had mitochondria showed numerous cytoplasmic green punctae located within the mitochondrial fibrillar network ([Figures 5](#fig5){ref-type="fig"}A and 5B, right panel, top row, arrows) representing mtDNA nucleoids that co-localized with MitoTracker Deep Red staining. Mito-HNK treatment inhibited cell proliferation in both parental cell lines by \>50% ([Figures 5](#fig5){ref-type="fig"}C and 5D), but showed only minimal effects on both ρ0 cell lines, indicating that loss of mitochondrial function abrogates the anti-proliferative effects of Mito-HNK. We further validated these findings using another approach, i.e., depleting host mtDNA with a truncated form of a viral UL12.5 gene ([Figure S10](#mmc1){ref-type="supplementary-material"}, related to [Figure 5](#fig5){ref-type="fig"}). These results strongly suggest that the anti-cancer effects of Mito-HNK are dependent on mitochondrial function.Figure 5Depletion of mtDNA Abrogates the Anti-Proliferative Effects of Mito-HNK in Lung Cancer Cells(A and B) Validation of the loss of activities of the mitochondrial complexes in ρ0 cells. (A and B, left panels) Permeabilized cells were assayed in medium containing 10 mM pyruvate and 1.5 mM malate (substrates for complex I) in mannitol and sucrose (MAS) buffer. The complex I-related oxygen consumption rate (OCR) was assayed immediately and verified by injecting rotenone (complex I inhibitor) as indicated. Then, complex II-related OCR was measured by supplying cells with succinate (substrate for complex II, 10 mM). Both malonate (complex II inhibitor, 10 mM) and antimycin A (complex III inhibitor, 20 μM) were injected where indicated. (A and B, right panels) Validation of the absence of mitochondria in ρ0 cells with PicoGreen staining for mtDNA. Arrows indicate mitochondria fibrillar network.(C and D) mtDNA depletion abrogates the anti-proliferative effects of Mito-HNK (0.4 μM, 48 hr) in both B16 and 143B ρ0 cells. (\*\*\*P \< 0.001 *vs.* B16 or 143b parental cells). Error bars indicate SD.

Role of mitoSTAT3 in Mediating the Effects of Mito-HNK on Lung Cancer Cells {#sec2.6}
---------------------------------------------------------------------------

Potential additional components of the mechanism by which Mito-HNK inhibits lung cancer brain metastasis were examined via the PathScan RTK Signaling Antibody Array ([Figure S8](#mmc1){ref-type="supplementary-material"}A, related to [Figure 6](#fig6){ref-type="fig"}), which has been used extensively to study mechanisms of candidate cancer drugs ([@bib44], [@bib63]). This array identified *mito*STAT3 as a potential target of Mito-HNK ([Figure 6](#fig6){ref-type="fig"}A). We validated the effects of Mito-HNK on *mito*STAT3 phosphorylation in lung cancer cells via western blot ([Figures 6](#fig6){ref-type="fig"}B and [S8](#mmc1){ref-type="supplementary-material"}B; Figure S8B related to [Figure 6](#fig6){ref-type="fig"}). Since AMPK and *mito*STAT3 can play important roles in regulating mitochondrial activity, apoptosis, proliferation, and migration ([@bib57], [@bib17], [@bib33], [@bib75], [@bib69]), we examined the effects of Mito-HNK on AMPK^Thr172^ and *mito*STAT3^Ser727^ phosphorylation by western blot ([Figure 6](#fig6){ref-type="fig"}B). Compared with HNK, Mito-HNK induced much stronger AMPK phosphorylation and potently inhibited *mito*STAT3^Ser727^ phosphorylation in both PC9-BrM3 and H2030-BrM3 cells. We then used the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas9) system to knock out STAT3 ([Figure S9](#mmc1){ref-type="supplementary-material"}, related to [Figure 6](#fig6){ref-type="fig"}). Cell lines were screened by polymerase chain reaction (PCR) and sequencing, and knockouts were confirmed by western blotting ([Figure 6](#fig6){ref-type="fig"}C). CRISPR significantly decreased STAT3 protein by \>80% ([Figure 6](#fig6){ref-type="fig"}C), and the anti-invasive and anti-proliferation effects of Mito-HNK (24 hr) were abrogated in the STAT3-deficient cells ([Figures 6](#fig6){ref-type="fig"}D and 6E). However, no direct binding of Mito-HNK to STAT3 was detected (*not shown*) using an anti-TPP^+^ antibody (obtained from Dr. Michael P. Murphy, Mitochondrial Biology Unit, Cambridge, UK).Figure 6Role of STAT3 in the Anti-proliferative and Anti-invasive Effects of HNK and Mito-HNK in Lung Cancer Cells(A) Results of the receptor tyrosine kinase proteomic array of H2030-BrM3 cells treated with HNK (20 μM) or Mito-HNK (0.2 μM) for 24 hr.(B) Western blot analysis of the effect of HNK (20 μM) and Mito-HNK (0.2 μM) on AMPK and STAT3 phosphorylation status in PC9-BrM3 and H2030-BrM3 cells.(C) Western blot to verify knockout and knockdown of STAT3 in H2030-BrM3 cells.(D and E) STAT3 knockout abrogates the anti-invasive and anti-proliferation effects of Mito-HNK (0.2 μM) in H2030-BrM3 cells. (D) Representative images and (E) the quantitative results of the cell invasion assay, \*\*\*p \< 0.001. Error bars indicate SE.

Pathway Analysis of the Downstream Mediators of Mito-HNK Therapy {#sec2.7}
----------------------------------------------------------------

As shown in [Figure 3](#fig3){ref-type="fig"}, Mito-HNK treatment for 4 weeks dramatically reduced the brain metastatic burden of H2030-BrM3 cells. We used SSRS (species-specific RNAseq analysis) to profile the gene expression changes in the H2030-BrM3 brain metastatic lesions remaining after 4 weeks of Mito-HNK treatment compared with the brain metastatic lesions in vehicle-treated control animals. The H2030-BrM3 cells remaining in the brain metastatic lesions of Mito-HNK-treated animals had 4,660 differentially expressed (DE) genes (false discovery rate \[FDR\] \<0.05) compared with vehicle-treated animals ([Table S2](#mmc2){ref-type="supplementary-material"}; related to [Figure 7](#fig7){ref-type="fig"}). The nonmalignant stroma of the remaining brain metastatic lesions in Mito-HNK-treated animals had 6,544 DE genes (FDR \<0.05) compared with the vehicle-treated mice ([Table S3](#mmc3){ref-type="supplementary-material"}, related to [Figure 7](#fig7){ref-type="fig"}), of which only 22% (1,444 DE genes) overlapped with DE genes in the human malignant cells. We used the Ingenuity IPA tool (Qiagen, Redwood City, CA) to assess the biological and molecular pathways that were differentially regulated between the malignant tumor cells and the nonmalignant stroma ([Figure 7](#fig7){ref-type="fig"}). Mito-HNK treatment strongly induced mediators of cell death (*Z* score: +2.5; p \< 10^−57^) in the human malignant H2030-BrM3 cells but not in the nonmalignant stroma ([Figure 7](#fig7){ref-type="fig"}A), indicating that the pro-apoptotic effects of Mito-HNK are largely specific to the malignant tumor. In addition, Mito-HNK treatment also significantly downregulated the pathways involved in tumor invasion and proliferation and altered multiple molecular pathways that have been implicated in all three cellular processes ([Figure 7](#fig7){ref-type="fig"}B). In comparison, the nonmalignant stroma of the H2030-BrM3 brain lesions in Mito-HNK-treated mice had significant downregulation of inflammatory and angiogenic pathways, as well as altered expression of multiple key pathways that contribute to these processes ([Figure 7](#fig7){ref-type="fig"}C). Collectively, these data suggest that, in addition to Mito-HNK\'s pro-apoptotic and anti-proliferative effects on the tumor cells, Mito-HNK also inhibits stromal cell pathways that typically support the formation and progression of metastatic lesions in the brain.Figure 7Analysis of Pathways Regulated by Mito-HNK Treatment in the Malignant Tumor Cells and Nonmalignant Stroma of H2030-BrM3 Brain Metastatic Lesions(A) RNAseq analysis to compare differentially expressed (DE) genes that regulate cell death in the malignant tumor and nonmalignant stroma of brain metastatic lesions of mice treated with the vehicle control (C) or Mito-HNK (MH).(B and C) Analysis of molecular pathways and cellular functions that are positively and negatively enriched (indicated by *Z* score) following Mito-HNK treatment in the malignant tumor cells (B) and nonmalignant stroma (C). The raw *Z* scores were normalized within tumor and stromal groups. Note that the significant enrichment of DE genes that induce cell death are highly upregulated only in the Mito-HNK-treated malignant tumor cells (*Z* score: +2.5; p \< 10^−57^). p Values are indicated on the graphs. Black bars indicate molecular pathways, and red bars indicate cellular function pathways.

Discussion {#sec3}
==========

Although higher dose of HNK can induce mitochondria-dependent apoptosis in cancer cells ([@bib31], [@bib45], [@bib35]), it is not specifically sequestered into cell mitochondria. By conjugating HNK with TPP^+^ to generate Mito-HNK, we markedly enhanced mitochondrial accumulation and the ability to block proliferation and invasion of brain metastatic human lung cancer cells. Low micromolar levels of Mito-HNK inhibit complex I, stimulate ROS, oxidize mitochondrial Prx3, and suppress *mito*STAT3^Ser727^ phosphorylation. These findings provide the first evidence that, by directly targeting mitochondrial complex I, Mito-HNK can have exceptional preventive and therapeutic efficacy to inhibit lung cancer growth and brain metastasis.

Mito-HNK (at 3.75 μmol/kg) significantly inhibited lung cancer metastases from growing in the brain, whereas this same dose of HNK does not inhibit brain metastasis. A 10-fold higher dose of HNK (37.5 μmol/kg, which equals to 10 mg/kg) is needed to inhibit brain metastasis ([@bib45], [@bib44]). Mito-HNK (3.75 μmol/kg) also inhibited lung tumor growth in orthotopic models of both NSCLC and SCLC. These results are consistent with the markedly greater potency and efficacy of Mito-HNK in inhibiting proliferation, migration, and invasion of lung cancer cells. These results further suggest that Mito-HNK can be effective regardless of the driver mutation status (mutant EGFR in PC9-BrM3 cells; mutant KRAS in H2030-BrM3 cells). Therefore this study constitutes a critical step toward the clinical translation of Mito-HNK for treating lung cancer and its metastases.

The constitutive activation (phosphorylation) of STAT3 in many tumors is important for tumor growth, survival, progression ([@bib48]), and metastasis ([@bib26]). Our data imply that *mito*STAT3 is another important molecular target of Mito-HNK. Mito-HNK (0.2 μM) suppressed the phosphorylation of STAT3 at Ser727 ([Figure 6](#fig6){ref-type="fig"}), and STAT3 knockout abrogated its anti-invasive effects ([Figures 6](#fig6){ref-type="fig"}D and 6E). Phosphorylation of STAT3 on Tyr705 promotes its nuclear translocation and its canonical activity as a transcription factor ([@bib57], [@bib17], [@bib33], [@bib75], [@bib69]). Phosphorylation at Ser727 also has important mitochondrial implications that are independent of its transcriptional role ([@bib48], [@bib73]). *Mito*STAT3 can inhibit the mitochondrial permeability transition pore and can promote optimal electron transport ([@bib48], [@bib66], [@bib59]). The effects of p-STAT3^Ser727^ on mitochondrial electron transport may not be direct, however, given that complexes I and II are about 10^5^ more abundant than *mito*STAT3 ([@bib46]). Of particular note, p-STAT3^Ser727^ can promote complex I activity and the transformation and growth of multiple cancers ([@bib74], [@bib23], [@bib75], [@bib6]). These effects are not dependent on p-STAT3^Tyr705^ ([@bib74], [@bib23], [@bib75], [@bib6]). The suppression of p-STAT3^Ser727^ could therefore be important for Mito-HNK\'s ability to suppress lung tumor growth, invasion, and metastasis. Cancer metastasis is a complex, multistep process including cell proliferation, invasion, self-renewal, and tumor cell immune evasion. Compelling evidence published in recent years has demonstrated that STAT3 activation plays a critical role in every step of metastasis ([@bib15]). Activated STAT3 could directly bind to the promoter of MMP (matrix metalloproteinases) genes, increase the expression of multiple MMPs, and lead to the extracellular matrix formation, ultimately promote cellular invasion ([@bib14], [@bib72], [@bib25], [@bib29]). Furthermore, STAT3 also modulates Rac1 or Rho activity to maintain directional persistence during migration ([@bib13], [@bib62]). STAT3 activation also upregulates the secretion of various immunosuppressive factors such as interleukin-6 and tumor necrosis factor-α ([@bib40]) and reduces the activity of NK cells ([@bib64]), and thereby protecting tumor cells during circulation.

Although there are multiple events by which Mito-HNK might function to decrease p-STAT3^Ser727^, it is unlikely that Mito-HNK directly affects STAT3, as no direct binding of Mito-HNK to STAT3 was detected. Rather, the data suggest that complex I inhibition, which occurs within minutes of Mito-HNK treatment, is upstream of the effects on *mito*STAT3. Specifically, Mito-HNK still inhibited complex I in cells in which STAT3 was knocked down (*not shown*), indicating that STAT3 is not required for complex I inhibition. Based on the data, we postulate a mechanism ([Figure 8](#fig8){ref-type="fig"}) in which complex I inhibition is a key initiating event that promotes the other observed effects. It is well recognized that complex I inhibition can stimulate mitochondrial ROS generation, consistent with the ROS data ([Figures 4](#fig4){ref-type="fig"}C and 4D) and the selective oxidation of mitochondrial Prx3 ([Figures 4](#fig4){ref-type="fig"}E and 4F). Since Prx3 represents ∼90% of total mitochondrial peroxidase activity ([@bib11]), these data indicate that Mito-HNK-induced ROS generation overwhelms the mitochondrial capacity to degrade peroxides. STAT3 is susceptible to oxidative inactivation ([@bib30], [@bib52]), and the levels of active p-STAT3^Ser727^ can be enhanced by antioxidants (e.g., glutathione, *N*-acetylcysteine) ([@bib6]). Although peroxides might conceivably oxidize STAT3 directly ([@bib30]), it is unlikely that STAT3 thiols would initially compete with Prxs for cellular H~2~O~2~ given the highly favorable kinetics of Prxs ([@bib11]). Oxidized Prxs can oxidize various proteins ([@bib5], [@bib19], [@bib20]), including STAT3 ([@bib57]), so pronounced Prx3 oxidation in Mito-HNK-treated cells is a logical link between enhanced mitochondrial ROS generation and inhibiting *mito*STAT3 function.Figure 8Proposed Mechanisms of the Antiproliferative and Anti-invasive Effects of HNK and Mito-HNKNADH dehydrogenase (complex I) plays a key role in regulating and maintaining mitochondrial function and energy production (ATP). Suppressing complex I activity can increase ROS production and signaling through ROS-associated pathways. We propose that one potential mechanism of action of Mito-HNK is that it inhibits complex I in lung cancer cells; stimulates ROS generation, which promotes oxidation of mitochondrial Prx3; activates AMPK; and inhibits STAT3^ser727^ phosphorylation and cell proliferation. The results indicate that Mito-HNK mediates these events more robustly and at much lower concentrations than does HNK.

We have shown that the increased *in vitro* potency of Mito-HNK over HNK is clear, and the antitumor activity of Mito-HNK in the *in vivo* tumor models ([Figures 2](#fig2){ref-type="fig"}F--2H and [3](#fig3){ref-type="fig"}F--3H) is impressive. Our observation that the compound has limited effects on normal cells or tissues ([Figure 1](#fig1){ref-type="fig"}) is most likely due to the unusually greater uptake and retention of mito-targeted compounds by cancer cells as a consequence of highly elevated mitochondrial and plasma membrane potentials. Thus the preferential accumulation of Mito-HNK in the mitochondria of cancer cells leads to highly potent anti-cancer effects with no observed toxicity in mice given 20-fold more than the effective dose for 8 weeks. Similarly, other mitochondria-targeted agents are less toxic to normal cells than tumorigenic cells ([@bib37], [@bib10]) and show no adverse effects with long-term administration in mice and humans ([@bib21], [@bib36]). Combining Mito-HNK with standard chemotherapeutics, such as cisplatin, could significantly increase the killing of cancer cells and, meanwhile, lower the effective doses of these chemotherapeutics ([Figure S11](#mmc1){ref-type="supplementary-material"}, related to [Figure 3](#fig3){ref-type="fig"}). The low toxicity of Mito-HNK, coupled with its ability to cross the BBB and the blood-CSF barrier ([@bib65], [@bib31]), make it a highly attractive therapeutic agent, alone or in combination with standard therapy, for lung cancer and its metastases to the brain.

The SSRS analysis of brain metastatic H2030-BrM3 cells in treated mice further demonstrate the on-target antitumor effects of Mito-HNK to activate cell death and anti-proliferative signaling pathways in the metastatic tumor cells ([Figures 7](#fig7){ref-type="fig"}A and 7B), whereas similar pathways were not induced in the nonmalignant stromal cells ([Figures 7](#fig7){ref-type="fig"}A and 7C). In the nonmalignant stroma, Mito-HNK significantly attenuated inflammatory and pro-angiogenic pathways ([Figure 7](#fig7){ref-type="fig"}C), which resembles similar stromal-dependent antitumor mechanisms reported for HNK ([@bib27], [@bib3]). Thus Mito-HNK is substantially more potent than HNK in targeting tumor cell mitochondria while maintaining its ability to suppress key components of the tumor stroma that can promote malignancy.

In summary, we demonstrate here the pronounced anti-cancer and anti-metastatic potential of Mito-HNK using both *in vitro* and *in vivo* lung cancer models. Mito-HNK potently inhibits orthotopic lung tumor growth as well as lung cancer metastasis to the brain. Mechanistically, we discovered, for the first time, that the ability of Mito-HNK to concentrate in the mitochondria renders it highly effective at inhibiting complex I, which corresponds with its ability to enhance mitochondrial ROS generation, promote Prx3 oxidation, suppress the phosphorylation of *mito*STAT3, and suppress the proliferation and invasion of cancer cells. The low toxicity of Mito-HNK, coupled with its ability to cross the BBB, makes it a highly attractive preventive and therapeutic agent for lung cancer and its brain metastases. Targeting of cancer cell mitochondrial bioenergetics represents a new strategy for treating lung cancer.
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All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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The authors declare that all data supporting the findings of this study are available within the article and its [Supplemental Information](#appsec2), and from the corresponding author upon reasonable request. The RNA-seq raw sequence reads data from the H2030-BrM3 brain metastatic lesions of nude mice treated with Mito-HNK or vehicle control for four weeks (n = 3 per group, total N = 6) as described in the Supplementary file have been deposited in the Sequence Read Archive under accession number of SRP144372. Mito-HNK will be freely distributed upon request to qualified academic investigators for non-commercial research. Primary or luciferase-tagged cancer cells will be distributed following completion of a material transfer agreement agreed upon by the Medical College of Wisconsin and the recipient organization. Costs to ship Mito-HNK or cancer cell lines generated by this project will be incurred by the requestor and will be shipped following all Federal guidelines and precautions to minimize loss.

Supplemental Information {#appsec3}
========================

Document S1. Transparent Methods, Figures S1--S11, and Table S1Table S2. Gene Expression in Malignant Tumor Cells from Brain Metastatic LesionsTable S3. Gene Expression in Nonmalignant Stromal Cells from Brain Metastatic Lesions

We are grateful to Dr. Joan Massage (Memorial Sloan Kettering Cancer Center) for providing the H2030-BrM3 and PC9-BrM3 cells, to O.V. (Roskilde University) for providing the 143B and 143B ρ0 cells, and to M.B. (Czech Academy of Sciences) for providing the B16 and B16 ρ0 cells. This work was funded by the NIH grant R01CA208648.

Author Contributions {#sec5}
====================

M.Y., B.K., J.P., and J.Z. were responsible for the overall experimental design with input from Y.L., G.C., D.X., M.F., C.M.O., and C.R.M. The project was supervised by M.Y., B.K., J.P., and J.Z. M.H. synthesized and characterized the mito-honokiols. C.M.O., J.P., and Q.Z. assessed the animal toxicity of Mito-HNK. G.C., J.P., and Y.L. did the cell proliferation and transwell invasion studies. J.P. and Y.L. did the tyrosine kinase assays, western blots, and STAT3 knockout and knockdown experiments. J.P., Y.L., Q.Z., and Y.W. conducted the orthotopic lung cancer and brain metastasis animal studies. M.F., D.X., and S.-W.T. did the RNA-seq analysis. J.P. and G.C. conducted the experiments with ρ0 cells. G.C. and J.Z. analyzed respiratory enzyme activity and intracellular oxidants. C.R.M. did the peroxiredoxin experiments. M.B., O.V., and J.N. provided rho0 or ρ0 cells. M.Y. and B.K. acquired the funding. The following were largely responsible for writing, reviewing, and editing the manuscript: J.P., G.C., J.Z., M.H., M.F., C.R.M., B.K., and M.Y.

Declaration of Interests {#sec6}
========================

The authors declare that there are no financial or other conflicts of interest.

Supplemental Information includes Transparent Methods, 11 figures, and 3 tables and can be found with this article online at [https://doi.org/10.1016/j.isci.2018.04.013](10.1016/j.isci.2018.04.013){#intref0010}.

[^1]: These authors contributed equally

[^2]: Lead Contact
